Refractory coeliac disease

Current Opinion in Oncology

Volumn 25, Issue 5, 2013, Pages 445-451

  Malamut, Georgia ^a,b   Cellier, Christophe ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Cytokine IL 15; Enteropathy associated T cell lymphoma; Phenotype of intraepithelial lymphocytes; Refractory coeliac disease

Indexed keywords

AZATHIOPRINE; CLADRIBINE; CYCLOSPORIN; JANUS KINASE 3 INHIBITOR; PENTOSTATIN;

CELIAC DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOUBLE BALLOON ENTEROSCOPY; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTESTINE ENDOSCOPY; INTESTINE ULCER; INTESTINE VILLUS ATROPHY; LYMPHOCYTE; LYMPHOMA; MALABSORPTION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY CELIAC DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; CLASSIFICATION; GLUTEN FREE DIET; PATHOLOGY; STOMACH NEOPLASMS;

CELIAC DISEASE; DIET, GLUTEN-FREE; HUMANS; LYMPHOMA; STOMACH NEOPLASMS;

EID: 84883221306     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/01.cco.0000432526.47228.b6     Document Type: Review

References (55)

1. Vahedi K, Mascart F, Mary JY, et al. Reliability of antitransglutaminase antibodies as predictors of gluten-free diet compliance in adult celiac disease. Am J Gastroenterol 2003; 98: 1079-1087.
2. Akram S, Murray JA, Pardi DS, et al. Adult autoimmune enteropathy: Mayo Clinic Rochester experience. Clin Gastroenterol Hepatol 2007; 5: 1282-1290.
3. Khokhar N, Gill ML. Tropical sprue: revisited. J Pak Med Assoc 2004; 54: 133-134.
4. Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol 2010; 105: 2262-2275.
5. Cellier C, Patey N, Mauvieux L, et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998; 114: 471-481.
6. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203-208.
7. Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009; 136: 81-90.
8. West J. Celiac disease and its complications: a time traveller's perspective. Gastroenterology 2009; 136: 32-34.
9. Roshan B, Leffler DA, Jamma S, et al. The incidence and clinical spectrum of refractory celiac disease in a North American referral center. Am J Gastroenterol 2011; 106: 923-928.
10. Rubio-Tapia A, Kelly DG, Lahr BD, et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009; 136: 99-107.
11. Daum S, Ipczynski R, Schumann M, et al. High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol 2009; 21: 66-70.
12. Al-Toma A, Verbeek WH, Hadithi M, et al. Survival in refractory coeliac disease and enteropathy associated T cell lymphoma: retrospective evaluation of single centre experience. Gut 2007; 56: 1373-1378.
13. Daum S, Cellier C, Mulder CJ. Refractory coeliac disease. Best Pract Res 2005; 19: 413-424.
14. Murray JA, Rubio-Tapia A, Van Dyke CT, et al. Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol 2008; 6: 186-193.
15. Malamut G, Murray JA, Cellier C. Refractory celiac disease. Gastrointestinal endoscopy clinics of North America 2012; 22: 759-772. This editorial discusses the differences observed in frequency of RCDI and RCDII between US and Europe.
16. Daum S, Wahnschaffe U, Glasenapp R, et al. Capsule endoscopy in refractory celiac disease. Endoscopy 2007; 39: 455-458.
17. Barret MMG, Rahmi G, Samaha A, et al. Diagnostic yield of capsule endoscopy in refractory celiac disease. Am J Gastroenterol 2012; 107: 1546-1553. This study highlights the interest of capsule endoscopy in the assessment of RCD and its complications.
18. Malamut G, Cellier C. Is refractory celiac disease more severe in old Europe? Am J Gastroenterol 2011; 106: 929-932.
19. Malamut G, Meresse B, Verkarre V, et al. Large granular lymphocytic leukemia complicating celiac disease: a rare cause of refractory celiac disease. Gastroenterology 2012; 143: 1470-1472. This is the first study to describe precisely large granular lymphocytic leukemia infiltrating the small bowel of coeliac patients and conferring by this way resistance to a GFD. It highlights the interest of flow cytometry analysis in discarding the causes of refractory coeliac disease.
20. Perfetti V, Brunetti L, Biagi F, et al. TCRbeta clonality improves diagnostic yield of TCRgamma clonality in refractory celiac disease. J Clin Gastroenterol 2012; 46: 675-679.
21. Goerres MS, Meijer JW, Wahab PJ, et al. Azathioprine and prednisone combination therapy in refractory coeliac disease. Aliment Pharmacol Ther 2003; 18: 487-494.
22. Verkarre V, Romana SP, Cellier C, et al. Recurrent partial trisomy 1q22-q44 in clonal intraepithelial lymphocytes in refractory celiac sprue. Gastroenterology 2003; 125: 40-46.
23. Malamut G, Verkarre V, Meresse B, et al. High rate of abnormal intestinal intraepithelial lymphocytes is predictive of extra-digestive diffusion in refractory coeliac disease. Abstract Gut 2008; 57 (Suppl II):A30.
24. Malamut G, Chandesris O, Verkarre V, et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis 2013; 45: 377-384. This is the first case series study which shows the impact of the type of enteropathy, nutritional status and debulking surgery on EATL prognosis.
25. Hoffmann M, Vogelsang H, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut 2003; 52: 347-351.
26. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000; 18: 795-803.
27. Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol 2003; 21: 2740-2746.
28. Al-Toma A, Goerres MS, Meijer JW, et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol 2006; 4: 315-319.
29. Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008; 359: 2767-2777.
30. Hunt KA, Zhernakova A, Turner G, et al. Newly identified genetic risk variants for celiac disease related to the immune response. NatGenet 2008; 40: 395-402.
31. Dubois PC, Trynka G, Franke L, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010; 42: 295-302.
32. Trynka G, Hunt KA, Bockett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43: 1193-1201.
33. Devalliere J, Charreau B. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling. Biochem Pharmacol 2011; 82: 1391-1402.
34. Mention JJ, Ben Ahmed M, Begue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003; 125: 730-745.
35. Askling J, Linet M, Gridley G, et al. Cancer incidence in a populationbased cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002; 123: 1428-1435.
36. Holmes GK, Prior P, Lane MR, et al. Malignancy in coeliac disease: effect of a gluten free diet. Gut 1989; 30: 333-338.
37. Biagi F, Corazza GR. Mortality in celiac disease. Nat Rev Gastroenterol Hepatol 2011; 7: 158-162.
38. Stene LC, Honeyman MC, Hoffenberg EJ, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006; 101: 2333-2340.
39. Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annual Rev Immunol 1999; 17: 19-49.
40. Foxman EF, Iwasaki A. Genome-virome interactions: examining the role of common viral infections in complex disease. Nat Rev Microbiol 2011; 9: 254-264.
41. Gough DJ, Messina NL, Clarke CJ, et al. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012; 36: 166-174.
42. Colpitts SL, Stoklasek TA, Plumlee CR, et al. Cutting edge: the role of IFN-alpha receptor and MyD88 signaling in induction of IL-15 expression in vivo. J Immunol 2012; 188: 2483-2487. The findings show how infection may be involved in up-regulation of IL-15 expression in myeloid lineages and give some pathogenic hypotheses on the role of viral infection in RCD.
43. Ciccocioppo R, Di Sabatino A, Parroni R, et al. Increased enterocyte apoptosis and Fas-Fas ligand system in celiac disease. Am J Clin Pathol 2001; 115: 494-503.
44. Di Sabatino A, Ciccocioppo R, D'Alo S, et al. Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis whereas both populations are active in Fas based cytotoxicity in coeliac disease. Gut 2001; 49: 380-386.
45. Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokineactivated killer cells in celiac disease. Immunity 2004; 21: 357-366.
46. Hue S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004; 21: 367-377.
47. Malamut G, El Machhour R, Montcuquet N, et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Investig 2010; 120: 2131-2143.
48. Dray X, Joly F, Lavergne-Slove A, et al. A severe but reversible refractory sprue. Gut 2006; 55: 1210-1211.
49. Al-Toma A, Goerres MS, Meijer JW, et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol 2006; 4: 1322-1327.
50. Al-Toma A, Visser OJ, van Roessel HM, et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T-cells. Blood 2007; 109: 2243-2249.
51. Tack GJ, Wondergem MJ, Al-Toma A, et al. Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant 2011; 46: 840-846.
52. Waldmann TA. Targeting the interleukin-15 system in rheumatoid arthritis. Arthritis Rheum 2005; 52: 2585-2588.
53. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64: 617-629.
54. Yokoyama S, Perera PY, Waldmann TA, et al. Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol 2013; 33: 586-594. The study presents the therapeutic effects of a JAK-3 inhibitor in a mouse model of RCDII.
55. Malamut G, Meresse B, Cellier C, Cerf-Bensussan N. Refractory celiac disease. Semin Immunopathol 2012; 34: 601-613.